WW International Launches New Integrated GLP-1 Experience Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Should l Buy WW?
WW International introduced a new, fully integrated experience that unites GLP-1 prescribing, personalized nutrition, behavioral support, coaching, and community within a redesigned app experience and digital platform. Built for a new era of weight management and long-term health, the new integrated offering delivers coordinated, evidence-based support that adapts to members' lives and helps them achieve-and sustain-superior results. Weight Watchers Med+ is the company's dedicated GLP-1 medical program, providing members access to board-certified physicians and a coordinated care team who specialize in obesity and metabolic health. These clinicians write prescriptions for GLP-1 medications for eligible members and offer ongoing medical guidance throughout treatment. What truly sets Med+ apart is that every member prescribed GLP-1s also receives the full GLP-1 Success experience-a structured behavioral, nutritional, and lifestyle support program that research shows achieves better results on medication. This newly launched GLP-1 Success program is built around the real needs of people using these medications. Members receive personalized nutrition guidance to help them meet important macronutrient goals, tools to track weight loss and medication doses, strategies and support for managing side effects, and strength-building plans to help preserve muscle mass. The program also provides access to expert coaches trained in GLP-1 support, and virtual community groups with others on a similar journey. By pairing medical care with the GLP-1 Success framework, Med+ delivers a complete solution that goes far beyond prescription-only services-and drives stronger outcomes for members than medication alone. In addition, more than 70% of Weight Watchers Med+ members on the GLP-1 Success Program say that it helps them minimize weight loss medication side effects. For those who receive their GLP-1 prescriptions from an alternative medical provider, Weight Watchers is also offering the GLP-1 Success Program as a standalone option. These members receive the same comprehensive lifestyle, nutrition, movement, coaching, and community support as those on Med+, ensuring that anyone taking GLP-1s can access the structure and guidance needed to use these medications safely, effectively and successfully. The new experience will be gradually rolling across the global market in the coming weeks, starting on Dec. 26. The Weight Watchers app is available on both iOs and Android providing a seamless and modern interface across devices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WW
Wall Street analysts forecast WW stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 14.060
Low
38.00
Averages
38.00
High
38.00
Current: 14.060
Low
38.00
Averages
38.00
High
38.00
About WW
WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
WW International Appoints Interim CEO Following Leadership Shakeup
- Executive Shakeup: WW International swiftly established an interim CEO office led by CFO Felicia DellaFortuna and COO Jonathan Volkmann following the abrupt resignation of CEO Tara Comonte on March 31, 2025, demonstrating the company's adaptability amid leadership changes.
- Legal Officer Resignation: Concurrently, Chief Legal and Administrative Officer Jaqueline Cooke resigned at the board's request effective April 10, further intensifying instability at the executive level, which could impact investor confidence.
- Performance Outlook Maintained: Despite the frequent executive turnover, WW International reaffirmed its Q1 and full-year outlook for 2026, projecting revenues between $620 million and $635 million, indicating the company's confidence in future earnings.
- Market Reaction: WW International's shares rallied as weight loss medications attracted new subscribers, suggesting that despite executive departures, the market remains optimistic about the company's growth potential.
See More
Weight Watchers Establishes CEO Office to Oversee Business Operations
- Leadership Changes: Weight Watchers has established an Office of the CEO to oversee business operations, with Felicia DellaFortuna and Jon Volkmann at the helm, aimed at ensuring effective execution of the company's strategy and maintaining operational stability.
- Transition Committee Formation: The Board has formed a Transition Committee to assist in the CEO search, including members like Gene Davis, ensuring that governance and board refreshment continue while a new leader is sought.
- Executive Appointment: Debra Cotter has been appointed as Chief Legal Officer, succeeding Jacqueline Cooke, highlighting the company's focus on legal affairs during this critical time to ensure compliance and governance continuity.
- Financial Guidance Reaffirmed: Weight Watchers reaffirmed its first quarter 2026 subscriber estimates and full-year financial guidance, demonstrating confidence in its business outlook amid leadership transitions.
See More
Nasdaq Rebounds as Oil Worries Subside and Tech Gains Drive Market
- Successful Financing: Century Lithium Corp. completed a C$7 million brokered private placement, issuing 14.89 million units to support its lithium operations in Nevada, which is expected to enhance its market competitiveness and drive future growth.
- Earnings Beat: WW International shares surged over 12% after reporting stronger-than-expected Q4 and full-year 2025 earnings despite a year-over-year revenue decline, indicating the company's resilience in challenging conditions.
- Strategic Partnership: Tower Semiconductor's stock rose over 11% following its announcement of a strategic partnership with Oriole Networks to develop photonic networking technologies aimed at improving AI infrastructure, showcasing the company's proactive approach to technological innovation.
- Government Support: First Phosphate Corp. secured a $16.7 million non-repayable contribution from the Canadian government to advance its Bégin-Lamarche phosphate project in Québec, which is expected to accelerate project progress and enhance the company's standing in the industry.
See More
WW International Reduces Debt by Over 70% and Repositions Brand
- Debt Reduction Success: WW International successfully emerged from Chapter 11 financial reorganization, reducing legacy debt by over 70%, which has freed up capital for future investments and enhanced the company's financial flexibility.
- Clinical Revenue Growth: The company reported a 32% increase in clinical revenue for Q4, driven by the successful launch of its Med+ offering and increased consumer interest in GLP-1 medications, demonstrating the effectiveness of its new strategy.
- User Growth and Brand Repositioning: 50% of new Med+ members are first-time users, indicating that the brand repositioning strategy has yielded positive results by attracting more new customers and expanding market share.
- Modernized Technology Infrastructure: WW International launched a new mobile app featuring an AI body scanner and personalized modes, significantly enhancing user experience and further driving member engagement and satisfaction.
See More
WW International Q4 Earnings: Transformation and Growth Insights
- Debt Reduction and Investment: WW International successfully reduced over 70% of its legacy debt post-bankruptcy, freeing up capital for future investments, with CEO Tara Comonte emphasizing this move as foundational for the company's technology modernization efforts.
- Clinical Subscriber Growth: As of Q4, clinical subscribers reached 130,000, with expectations to grow to approximately 200,000 by the end of Q1, indicating nearly 100% year-over-year growth and showcasing the company's adaptability in the GLP-1 medication era.
- Financial Performance and Outlook: Q4 total revenue was $163 million, down 12% year-over-year, yet clinical revenue grew by 32%, with management projecting 2026 revenue between $620 million and $635 million, reflecting confidence in future growth.
- Market Strategy Shift: The company is transitioning from standalone behavioral offerings to an integrated weight health ecosystem, aiming to recapture lapsed subscribers and drive clinical growth, demonstrating a keen awareness of market changes.
See More
WW International's Transformation Drives Subscriber Growth
- Significant Subscriber Growth: WW International's transformation to include GLP-1 offerings resulted in a 42% increase in subscribers, indicating initial success in attracting customers and enhancing market competitiveness.
- Clinical Revenue Boost: Clinical subscription revenue rose by 32% year-over-year by the end of Q4, alleviating the impact of a 12% decline in total revenue and showcasing the potential for future income growth in new business areas.
- Stock Price Surge: The company's shares opened more than 14% higher on Monday, reflecting positive market sentiment towards its transformation strategy, despite reporting a loss of $0.58 per share, which was better than Wall Street's expectations.
- Optimistic Future Outlook: WW International anticipates FY26 sales between $620 million and $635 million, slightly below the $633.4 million estimate, but with adjusted EBITDA expectations of $105 million to $115 million, demonstrating confidence in future growth.
See More
WW International Appoints Interim CEO Following Leadership Shakeup
- Executive Shakeup: WW International swiftly established an interim CEO office led by CFO Felicia DellaFortuna and COO Jonathan Volkmann following the abrupt resignation of CEO Tara Comonte on March 31, 2025, demonstrating the company's adaptability amid leadership changes.
- Legal Officer Resignation: Concurrently, Chief Legal and Administrative Officer Jaqueline Cooke resigned at the board's request effective April 10, further intensifying instability at the executive level, which could impact investor confidence.
- Performance Outlook Maintained: Despite the frequent executive turnover, WW International reaffirmed its Q1 and full-year outlook for 2026, projecting revenues between $620 million and $635 million, indicating the company's confidence in future earnings.
- Market Reaction: WW International's shares rallied as weight loss medications attracted new subscribers, suggesting that despite executive departures, the market remains optimistic about the company's growth potential.
See More
Weight Watchers Establishes CEO Office to Oversee Business Operations
- Leadership Changes: Weight Watchers has established an Office of the CEO to oversee business operations, with Felicia DellaFortuna and Jon Volkmann at the helm, aimed at ensuring effective execution of the company's strategy and maintaining operational stability.
- Transition Committee Formation: The Board has formed a Transition Committee to assist in the CEO search, including members like Gene Davis, ensuring that governance and board refreshment continue while a new leader is sought.
- Executive Appointment: Debra Cotter has been appointed as Chief Legal Officer, succeeding Jacqueline Cooke, highlighting the company's focus on legal affairs during this critical time to ensure compliance and governance continuity.
- Financial Guidance Reaffirmed: Weight Watchers reaffirmed its first quarter 2026 subscriber estimates and full-year financial guidance, demonstrating confidence in its business outlook amid leadership transitions.
See More
Nasdaq Rebounds as Oil Worries Subside and Tech Gains Drive Market
- Successful Financing: Century Lithium Corp. completed a C$7 million brokered private placement, issuing 14.89 million units to support its lithium operations in Nevada, which is expected to enhance its market competitiveness and drive future growth.
- Earnings Beat: WW International shares surged over 12% after reporting stronger-than-expected Q4 and full-year 2025 earnings despite a year-over-year revenue decline, indicating the company's resilience in challenging conditions.
- Strategic Partnership: Tower Semiconductor's stock rose over 11% following its announcement of a strategic partnership with Oriole Networks to develop photonic networking technologies aimed at improving AI infrastructure, showcasing the company's proactive approach to technological innovation.
- Government Support: First Phosphate Corp. secured a $16.7 million non-repayable contribution from the Canadian government to advance its Bégin-Lamarche phosphate project in Québec, which is expected to accelerate project progress and enhance the company's standing in the industry.
See More
WW International Reduces Debt by Over 70% and Repositions Brand
- Debt Reduction Success: WW International successfully emerged from Chapter 11 financial reorganization, reducing legacy debt by over 70%, which has freed up capital for future investments and enhanced the company's financial flexibility.
- Clinical Revenue Growth: The company reported a 32% increase in clinical revenue for Q4, driven by the successful launch of its Med+ offering and increased consumer interest in GLP-1 medications, demonstrating the effectiveness of its new strategy.
- User Growth and Brand Repositioning: 50% of new Med+ members are first-time users, indicating that the brand repositioning strategy has yielded positive results by attracting more new customers and expanding market share.
- Modernized Technology Infrastructure: WW International launched a new mobile app featuring an AI body scanner and personalized modes, significantly enhancing user experience and further driving member engagement and satisfaction.
See More
WW International Q4 Earnings: Transformation and Growth Insights
- Debt Reduction and Investment: WW International successfully reduced over 70% of its legacy debt post-bankruptcy, freeing up capital for future investments, with CEO Tara Comonte emphasizing this move as foundational for the company's technology modernization efforts.
- Clinical Subscriber Growth: As of Q4, clinical subscribers reached 130,000, with expectations to grow to approximately 200,000 by the end of Q1, indicating nearly 100% year-over-year growth and showcasing the company's adaptability in the GLP-1 medication era.
- Financial Performance and Outlook: Q4 total revenue was $163 million, down 12% year-over-year, yet clinical revenue grew by 32%, with management projecting 2026 revenue between $620 million and $635 million, reflecting confidence in future growth.
- Market Strategy Shift: The company is transitioning from standalone behavioral offerings to an integrated weight health ecosystem, aiming to recapture lapsed subscribers and drive clinical growth, demonstrating a keen awareness of market changes.
See More
WW International's Transformation Drives Subscriber Growth
- Significant Subscriber Growth: WW International's transformation to include GLP-1 offerings resulted in a 42% increase in subscribers, indicating initial success in attracting customers and enhancing market competitiveness.
- Clinical Revenue Boost: Clinical subscription revenue rose by 32% year-over-year by the end of Q4, alleviating the impact of a 12% decline in total revenue and showcasing the potential for future income growth in new business areas.
- Stock Price Surge: The company's shares opened more than 14% higher on Monday, reflecting positive market sentiment towards its transformation strategy, despite reporting a loss of $0.58 per share, which was better than Wall Street's expectations.
- Optimistic Future Outlook: WW International anticipates FY26 sales between $620 million and $635 million, slightly below the $633.4 million estimate, but with adjusted EBITDA expectations of $105 million to $115 million, demonstrating confidence in future growth.
See More
